McKesson will acquire Precision Medicine Group in a deal valued at about $2.25 billion, positioning the distributor and services company deeper into clinical research and biopharma commercialization. The acquisition would combine McKesson’s healthcare distribution network with Precision’s biomarker intelligence, laboratory services, clinical trial management, market access consulting and commercialization support. Once completed and subject to regulatory approval, Precision will fold into McKesson’s oncology and multispecialty segment. The deal is framed as a way to bridge development-to-market execution, particularly for smaller biotech companies that need operational capacity for complex studies and launches. For the biotech ecosystem, the transaction may increase leverage for sponsors seeking integrated trial execution and commercialization services—especially where biomarker-driven development and payer navigation determine speed to revenue.